
April 2004
Advertisement
Advertisement
Trending on HCPLive
1
How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD
2
What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata
3
FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis
4
Diabetes Dialogue: The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB
5